Holen Sie sich die Stockscreener-App
11.83
1.66%
-0.20
Handel nachbörslich:
11.83
Schlusskurs vom Vortag:
$12.03
Offen:
$12.13
24-Stunden-Volumen:
472.86K
Relative Volume:
2.47
Marktkapitalisierung:
$1.51B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.17%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.78
$12.85
1-Wochen-Bereich:
$11.78
$12.85
52-Wochen-Spanne:
$11.00
$13.95
Generate Biomedicines Inc Stock (GENB) Company Profile
Firmenname
Generate Biomedicines Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare GENB vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
11.83 | 1.53B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Generate Biomedicines Inc Aktie (GENB) Neueste Nachrichten
Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler - Seeking Alpha
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Piper Sandler - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Goldman Sachs Initiates Coverage on Generate Biomedicines With Buy Rating, $26 Price Target - marketscreener.com
Guggenheim Initiates Coverage on Generate Biomedicines With Buy Rating, $30 Price Target - marketscreener.com
This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target - marketscreener.com
Morgan Stanley initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Goldman Sachs initiates Generate Biomedicines stock with buy rating on AI platform potential - Investing.com Canada
Guggenheim initiates Generate Biomedicines stock with buy rating - Investing.com
Guggenheim initiates Generate Biomedicines stock with buy rating By Investing.com - Investing.com UK
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Generate Biomedicines IPO Turns Heads - Yahoo! Finance Canada
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Free cash flow per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total debt per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Revenue per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) 10K Form and SEC Filings 2026 - MarketBeat
Total liabilities & shareholders' equities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
After tax other income/expense of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
EBIT of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Pretax income of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Income Statement – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Dividends – NASDAQ:GENB - TradingView
Net debt of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Tangible book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Cash from investing activities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Free cash flow of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Cash Flow – NASDAQ:GENB - TradingView
Long term debt to total assets ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total liabilities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Enterprise value to EBITDA ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to sales ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB News Today | Why did Generate Biomedicines stock go down today? - MarketBeat
Working capital per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Total equity of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
Return on assets % of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total assets of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to cash flow ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total common shares outstanding of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (NASDAQ: GENB) holder reports 1.56M-share stake - Stock Titan
GENB SEC FilingsGenerate Biomedicines 10-K, 10-Q, 8-K Forms - Stock Titan
Generate Biomedicines (GENB) Stock Forecast and Price Target 2026 - MarketBeat
Fpn Ii, L.p. Net Worth (2026) - GuruFocus
Generate Biomedicines (GENB) Stock Chart and Price History 2026 - MarketBeat
Goodwin Advises Generate Biomedicines, Inc. On The Closing Of Its $400 Million Initial Public Offering - Mondaq
Finanzdaten der Generate Biomedicines Inc-Aktie (GENB)
Es liegen keine Finanzdaten für Generate Biomedicines Inc (GENB) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):